Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in research ...

Donanemab is a targeted antibody drug which slows down the early stages of Alzheimer’s. The drug, and another new drug for ...

A new Alzheimer’s drug has been rejected by the health spending watchdog for general use within NHS England, with the ...

There are four dementia-specific medications approved in Australia – donepezil, galantamine, rivastigmine, and memantine.

The U.K. watchdog declines to endorse Eli Lilly's Alzheimer's drug donanemab, citing lack of value for the NHS and ...

A drug that can slow the progression of Alzheimer's disease has been blocked for use on the NHS due to cost concerns.

Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of ...

A second groundbreaking drug (donanemab) for Alzheimer's disease has been rejected for widespread use by the NHS in England ...

Donanemab is a targeted antibody drug which slows the early stages of Alzheimer’s. Alzheimer’s Research UK said Nice's announcement “risks signalling that the UK is no longer a good place to launch ...

Eli Lilly's donanemab receives UK approval for mild cognitive impairment and mild dementia due to Alzheimer's disease.

For the second time in recent months, a U.K. agency said the limited benefits of a new Alzheimer’s drug do not justify its ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved US pharma major Eli Lilly’s Kisunla (donanemab ...